ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive
ANGLE is a world leading liquid biopsy company with sample to answer solutions.

ANGLE’s proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE’s Parsortix PC1 Clinical system is cleared by the FDA for the capture and harvest of circulating tumor cells (CTCs) from metastatic breast cancer patient blood for subsequent, user-validated analysis and has a CE-IVD mark for the intended clinical use.